Iris K. Minichmayr

1.4k total citations · 1 hit paper
31 papers, 594 citations indexed

About

Iris K. Minichmayr is a scholar working on Pharmacology, Epidemiology and Infectious Diseases. According to data from OpenAlex, Iris K. Minichmayr has authored 31 papers receiving a total of 594 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Pharmacology, 13 papers in Epidemiology and 7 papers in Infectious Diseases. Recurrent topics in Iris K. Minichmayr's work include Antibiotics Pharmacokinetics and Efficacy (22 papers), Pneumonia and Respiratory Infections (8 papers) and Antibiotic Resistance in Bacteria (7 papers). Iris K. Minichmayr is often cited by papers focused on Antibiotics Pharmacokinetics and Efficacy (22 papers), Pneumonia and Respiratory Infections (8 papers) and Antibiotic Resistance in Bacteria (7 papers). Iris K. Minichmayr collaborates with scholars based in Austria, Germany and Sweden. Iris K. Minichmayr's co-authors include Charlotte Kloft, Lena E. Friberg, Sebastian G. Wicha, Jan‐Willem C. Alffenaar, Anne‐Grete Märtson, Birgit C. P. Koch, Elisabet I. Nielsen, Michael Zöller, Christina Scharf and Markus Zeitlinger and has published in prestigious journals such as Advanced Drug Delivery Reviews, Pharmaceutical Research and Clinical Pharmacology & Therapeutics.

In The Last Decade

Iris K. Minichmayr

25 papers receiving 586 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

From Therapeutic Drug Monitoring to Model‐Informed Precision Dosing for Antibiotics

2021 180 citations Sebastian G. Wicha, Anne‐Grete Märtson et al. Clinical Pharmacology & Therapeutics profile →

Peers

Countries citing papers authored by Iris K. Minichmayr

Since Specialization

Citations

This map shows the geographic impact of Iris K. Minichmayr's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Iris K. Minichmayr with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Iris K. Minichmayr more than expected).

Fields of papers citing papers by Iris K. Minichmayr

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Iris K. Minichmayr. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Iris K. Minichmayr. The network helps show where Iris K. Minichmayr may publish in the future.

Co-authorship network of co-authors of Iris K. Minichmayr

This figure shows the co-authorship network connecting the top 25 collaborators of Iris K. Minichmayr. A scholar is included among the top collaborators of Iris K. Minichmayr based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Iris K. Minichmayr. Iris K. Minichmayr is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Seasons of Growth: Reflections on the CPT Editor‐in‐Training Program 2025 ·Clinical Pharmacology & Therapeutics ·(unknown), (unknown), (unknown), (unknown), (unknown), Karen E. Brown, Iris K. Minichmayr, D. Max Smith, Emily J. Cicali, Mohamed H. Shahin, Kathleen M. Giacomini, Piet H. van der Graaf	0
2	Dose individualisation of antibiotics in critically ill patients with inflammation: A narrative review 2025 ·British Journal of Clinical Pharmacology ·Sarah Dräger, Iris K. Minichmayr, Narges Alipanah, Erin F. Barreto, Lieuwe D. J. Bos, Lucas M. Fleuren, Nicole Hunfeld, (unknown), Sophie L. Stocker, João Paulo Telles, Antoni Torres, Birgit C. P. Koch, Henrik Endeman	0
3	Empowering Early‐Career Scientists: Opportunities Through ASCPT Programs, Networks, and Communities 2025 ·Clinical Pharmacology & Therapeutics ·S.C. Sharma, (unknown), Iris K. Minichmayr, Natasha Strydom, (unknown), (unknown), Tao Long, Sonya Tang Girdwood, Akinyemi Oni‐Orisan, (unknown), Dan Li	0
4	Single‐dose and steady‐state pharmacokinetics of clomipramine, yohimbine and clomipramine/yohimbine combination: A clinical drug–drug interaction study 2024 ·British Journal of Clinical Pharmacology ·(unknown), (unknown), Martin Bauer, Iris K. Minichmayr, Birgit Reiter, (unknown), (unknown), Maria Weber, (unknown), Marie Spies, Maysa Sarhan, (unknown), (unknown), (unknown), Markus Zeitlinger	0
5	PK/PD modelling and simulation of longitudinal meropenem in vivo effects against Escherichia coli and Klebsiella pneumoniae strains with high MICs 2024 ·International Journal of Antimicrobial Agents ·(unknown), Elisabet I. Nielsen, Jon Hansen, Edgars Liepinsh, Iris K. Minichmayr, Lena E. Friberg	1
6	Best Practice for Therapeutic Drug Monitoring of Infliximab: Position Statement from the International Association of Therapeutic Drug Monitoring and Clinical Toxicology 2024 ·Therapeutic Drug Monitoring ·Dahham Alsoud, Dirk Jan A. R. Moes, Zhigang Wang, (unknown), (unknown), Murray L. Barclay, Tomoyuki Mizuno, Iris K. Minichmayr, Ron J. Keizer, Sebastian G. Wicha, Gertjan Wolbink, Jo Lambert, Séverine Vermeire, Annick de Vries, Konstantinos Papamichael, Núria Padullés Zamora, Erwin Dreesen	8
7	Impact of continuous-infusion meropenem degradation and infusion bag changes on bacterial killing of Pseudomonas aeruginosa based on model-informed translation 2024 ·International Journal of Antimicrobial Agents ·Iris K. Minichmayr, Lena E. Friberg	1
8	Target-site cefiderocol pharmacokinetics in soft tissues of healthy volunteers 2024 ·Journal of Antimicrobial Chemotherapy ·(unknown), (unknown), (unknown), Anselm Jorda, (unknown), Felix Bergmann, Edith Lackner, (unknown), J. G. Coen van Hasselt, Iris K. Minichmayr, Christoph Dorn, Markus Zeitlinger, (unknown)	5
9	Model-informed precision dosing: State of the art and future perspectives 2024 ·Advanced Drug Delivery Reviews ·Iris K. Minichmayr, Erwin Dreesen, Marco Centanni, Zhigang Wang, (unknown), Lena E. Friberg, Sebastian G. Wicha	27
10	Concentrations of ceftazidime and avibactam in bile fluid—a prospective phase IIb study 2024 ·Journal of Antimicrobial Chemotherapy ·(unknown), (unknown), Iris K. Minichmayr, (unknown), Christoph Dorn, (unknown), Michael Adamzik, Hartmuth Nowak, Tim Rahmel	0
11	Distribution of Bevacizumab into the Cerebrospinal Fluid of Children and Adolescents with Recurrent Brain Tumors 2024 ·Pediatric Drugs ·Iris K. Minichmayr, (unknown), Johannes Gojo, Daniel Senfter, Christine Haberler, Amedeo A. Azizi, Lisa Mayr, Markus Zeitlinger, Andreas Peyrl	1
12	Multistate modeling for survival analysis in critically ill patients treated with meropenem 2023 ·CPT Pharmacometrics & Systems Pharmacology ·(unknown), Iris K. Minichmayr, (unknown), (unknown), Lena E. Friberg	4
13	Impact of Key Components of Intensified Ceftaroline Dosing on Pharmacokinetic/Pharmacodynamic Target Attainment 2023 ·Clinical Pharmacokinetics ·Iris K. Minichmayr, Sebastian G. Wicha, Peter Matzneller, Charlotte Kloft, Markus Zeitlinger	1
14	Towards model-informed precision dosing of piperacillin: multicenter systematic external evaluation of pharmacokinetic models in critically ill adults with a focus on Bayesian forecasting 2023 ·Intensive Care Medicine ·(unknown), Alexander Brinkmann, Anka C. Roehr, Otto Frey, Stefan Hagel, Christoph Dorn, Amélie Marsot, (unknown), Michael Zöller, Thomas Saller, Johannes Zander, (unknown), Christina Scharf, Josef Briegel, Iris K. Minichmayr, Sebastian G. Wicha, Uwe Liebchen	20
15	Model-Informed Translation of In Vitro Effects of Short-, Prolonged- and Continuous-Infusion Meropenem against Pseudomonas aeruginosa to Clinical Settings 2022 ·Antibiotics ·Iris K. Minichmayr, (unknown), Margreke J. E. Brill, Lena E. Friberg	4
16	Pharmacokinetic/pharmacodynamic models for time courses of antibiotic effects 2022 ·International Journal of Antimicrobial Agents ·Iris K. Minichmayr, Vincent Aranzana‐Climent, Lena E. Friberg	28
17	From Therapeutic Drug Monitoring to Model‐Informed Precision Dosing for Antibiotics breakdown → 2021 ·Clinical Pharmacology & Therapeutics ·Sebastian G. Wicha, Anne‐Grete Märtson, Elisabet I. Nielsen, Birgit C. P. Koch, Lena E. Friberg, Jan‐Willem C. Alffenaar, Iris K. Minichmayr	180
18	Role of renal function in risk assessment of target non-attainment after standard dosing of meropenem in critically ill patients: a prospective observational study 2017 ·Critical Care ·(unknown), Michael Zöller, Iris K. Minichmayr, Christina Scharf, Bárbara Maier, (unknown), Niklas Hartung, Wilhelm Huisinga, Michael Vogeser, Lorenz Frey, Johannes Zander, Charlotte Kloft	58
19	Pharmacokinetics of doripenem in plasma and epithelial lining fluid (ELF): comparison of two dosage regimens 2017 ·European Journal of Clinical Pharmacology ·(unknown), Iris K. Minichmayr, Robert Sauermann, Daniela Marhofer, Edith Lackner, Walter Jäger, Alexandra Maier‐Salamon, Richard Schwameis, Charlotte Kloft, Markus Zeitlinger	11
20	Population pharmacokinetics meets microdialysis: Benefits, pitfalls and necessities of new analysis approaches for human microdialysis data 2013 ·European Journal of Pharmaceutical Sciences ·(unknown), Iris K. Minichmayr, Charlotte Kloft	12

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact